AstraZeneca completes Omthera purchase
19th Jul 2013 07:23
AstraZeneca has strengthened its late-stage cardiovascular disease pipeline after completing the acquisition of New Jersey-based specialty pharmaceutical company Omthera Pharmaceuticals. The purchased company is focused on the development and commercialisation of new therapies for abnormal levels
Read moreLondon midday: Banks, miners provide a lift after China data
15th Jul 2013 11:42
Cyclical stocks welcomed in-line gross domestic product (GDP) figures from China on Monday morning with the FTSE 100 nearly hitting seven-week highs early on. London's benchmark index started the new week trading near the 6,600 level; the last time the FTSE 100 closed higher was on May 30th. Gains
Read moreLondon open: FTSE 100 near seven-week high after China data
15th Jul 2013 08:24
Worries about a sharp slowdown in China temporarily eased on Monday morning, pushing the FTSE 100 to levels not seen in nearly seven weeks. London's benchmark index started the new week trading near the 6,600 level early on. The last time the FTSE 100 closed higher was on May 30th. "European marke
Read moreLondon pre-open: Gains expected after in-line Chinese data
15th Jul 2013 07:29
A broadly in-line set of economic figures from China provided stock markets in Asia with a small boost on Monday, with London's FTSE 100 expected to follow suit early on. As expected, the annual rate of Chinese economic growth slowed down in the second quarter, from 7.7% to 7.5%. This will come as
Read moreAstraZeneca CFO leaves to join BG Group
15th Jul 2013 07:03
AstraZeneca's Chief Financial Officer (CFO) Simon Lowth is stepping down to join oil and gas firm BG Group. He will leave the pharmaceutical giant in October, after reporting third quarter results, and will start as BG Group's new CFO the following month. AstraZeneca has started to search for a r
Read moreFriday broker round-up UPDATE
12th Jul 2013 08:11
Ashmore Group: Morgan Stanley cuts target price from 444p to 420p and leaves its equal-weight rating unchanged. JP Morgan ups target price from 339p to 377p maintaining a neutral rating. AstraZeneca: Jefferies reduces target price from 3560p to 3400p, while keeping its hold recommendation. Aviva:
Read moreLondon pre-open: FTSE 100 expected to consolidate recent gains
28th Jun 2013 07:32
The FTSE 100 is expected to open flat to slightly higher on Friday morning as markets head into the final trading day of the second quarter. City sources predict the FTSE 100 will open up around six points from yesterday's close of 6,243. The index has delivered solid gains over the past three con
Read moreAstraZeneca completes acquisition of Pearl Therapeutics
28th Jun 2013 07:02
FTSE 100-listed biopharmaceutical business AstraZeneca has completed the acquisition of Pearl Therapeutics, a California-based company focused on the development of inhaled small-molecule therapeutics for respiratory disease. Upon completion of the merger, AstraZeneca acquired 100% of Pearl's shar
Read moreLondon pre-open: Tentative start expected as markets wait for Fed meeting
19th Jun 2013 07:25
Stocks are expected to open with only small gains on Wednesday morning as nervous investors refrain from building positions ahead of the Federal Reserve policy announcement after the market-close this evening. City sources predict the FTSE 100 will open up just eight points from yesterday's close o
Read moreAstraZeneca announces results of SAVOR study
19th Jun 2013 07:02
AstraZeneca has completed the fourth phase of its clinical trial of diabetes treatment Onglyza. Data from the SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial is being analysed and will be submitted to the European Society of Car
Read moreAstraZeneca sets up new headquarters in Cambridge
18th Jun 2013 13:07
Pharmaceutical company AstraZeneca is launching its global headquarters at the Cambridge Biomedical Campus. The research and development(R&D) site, which is expected to be open by 2016, is a £330m project. It will replace R&D at Alderley Park in Cheshire which will cease operations. The company
Read moreTuesday tips round-up: Xaar, AstraZeneca, Gemfields
11th Jun 2013 07:17
Since having floated itself back in 1996 at about a quid, inkjet printing technology outfit Xaar has metamorphosed into the market leader for the digital technology used to produce ceramic tiles ? a huge market, especially in China. About 15 per cent of tiles are produced digitally at present, but t
Read moreBroker tips: Lloyds, AstraZeneca, Betfair
10th Jun 2013 10:48
Investec has retained its 'sell' rating and 50p target price for part-nationalised lender Lloyds as speculation continues to increase ahead of a potential reprivatisation. The broker said it sees "little justification for the share price to react favourably" under the proposal from the Policy Excha
Read moreBroker snap: Pamure hails AstraZeneca's latest purchase
10th Jun 2013 10:32
Panmure Gordon has retained its 'hold' rating and 3,200p target price for biopharmaceutical group AstraZeneca, but celebrated the company's 560m-dollar acquisition of Pearl Therapeutics on Monday, a necessary move in the broker's opinion. The firm announced that it has entered into an agreement to
Read moreAstraZeneca to acquire Pearl Therapeutics to strengthen drug pipeline
10th Jun 2013 07:14
FTSE 100-listed global pharmaceuticals group AstraZeneca has entered into a definitive agreement to acquire Redwood City-based Pearl Therapeutics, an update issued by the group has shown. Pearl Therapeutics is a privately held company focused on the development of inhaled small-molecule therapeuti
Read more